Hunan Provincial Clinical Research Center for Metabolic Associated Fatty Liver Disease, Affiliated Nanhua Hospital, Hengyang Medical School & University of South China, Hengyang, Hunan 421002, China.
Department of Gastroenterology, Affiliated Nanhua Hospital, Hengyang Medical School & University of South China, Hengyang, Hunan 421002, China.
Chin Med Sci J. 2023 Dec;38(4):286-296. doi: 10.24920/004220.
Metabolic associated fatty liver disease (MAFLD) has become a prevalent chronic liver disease worldwide because of lifestyle and dietary changes. Gut microbiota and its metabolites have been shown to play a critical role in the pathogenesis of MAFLD. Understanding of the function of gut microbiota and its metabolites in MAFLD may help to elucidate pathological mechanisms, identify diagnostic markers, and develop drugs or probiotics for the treatment of MAFLD. Here we review the pathogenesis of MAFLD by gut microbiota and its metabolites and discuss the feasibility of treating MAFLD from the perspective of gut microbes.
代谢相关脂肪性肝病（MAFLD）是一种与生活方式和饮食改变相关的全球流行的慢性肝脏疾病。肠道微生物群及其代谢产物在 MAFLD 的发病机制中起着关键作用。了解肠道微生物群及其代谢产物在 MAFLD 中的功能可能有助于阐明病理机制、识别诊断标志物，并开发用于治疗 MAFLD 的药物或益生菌。本文主要从肠道微生物群及其代谢产物的角度探讨 MAFLD 的发病机制，并就从肠道微生物群治疗 MAFLD 的可行性进行讨论。
Front Endocrinol (Lausanne). 2021
Ther Adv Endocrinol Metab. 2024-9-25
Zotero 插件